Clinical trials: Hematopoietic Stem Cell Transplantations
Stem Cell Transplantation
Implementation and Testing of an eHealth Integrated Model of Care for Patients Receiving Allogeneic Stem Cell Transplantation: The SMILe Project
Numerous publications call for innovation based on integrated care principles, investment in self-management and use of eHealth to improve outcomes for allogeneic Stem Cell Transplant (alloSCT).
- Trial name
- NCT04789863
- Testing
- SMILe-Integrated Care Model, Usual Care
- Where
- Switzerland
- Volunteers
- 80 people
- Sponsor
- University of Basel
Hematologic Malignancy
Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor
This study will test whether half matched donors with favorable KIR genes will reduce the risk of cancer recurring after transplant.
- Trial name
- NCT02880293
- Testing
- melphalan, fludarabine, thiotepa
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Autologous Hematopoietic Stem Cell Transplant
Evaluation of the Safety of Cytokine-Induced-Killer Cells During Early Transplant Period of Autologous Hematopoietic Stem Cell Transplant Recipients.
The goal of this clinical study is to evaluate the safety of cytokine-induced-killer (CIK) cells during early transplant period of autologous hematopoietic stem cell transplant.
- Trial name
- NCT07692607
- Testing
- CIK cells
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- LucasBio
Graft-versus-host Disease, Poor Graft Function
Mesenchymal Stem Cell Infusion as Treatment for Steroid-Resistant Acute Graft Versus Host Disease (GVHD) or Poor Graft Function
The present project aims at investigating the role of MSC for the treatment of patients with Part 1: Steroid-refractory grade II-IV acute GVHD.
- Conditions
- Graft-versus-host Disease, Poor Graft Function, Low Donor T-cell Chimerism
- Trial name
- NCT00603330
- Testing
- Mesenchymal stem cells
- Where
- 12 sites in Belgium, Netherlands
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Liege
Hematopoietic and Lymphatic System Neoplasm
Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial
This phase II trial studies how well adding axatilimab to standard of care (SOC) therapy works in preventing graft versus host disease (GVHD) following allogeneic hematopoietic stem cell transplantation (HCT) in patients with…
- Trial name
- NCT07349771
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Axatilimab, Biospecimen Collection
- Where
- 3 sites in United States
- Sponsor
- Mayo Clinic
Hematopoietic Organs; Disorder
Probiotic Use in Children Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
Primary Objective: 1. To evaluate the safety of orally administered Lactobacillus plantarum strains 299 and 299v, a probiotic, in patients undergoing allogeneic myeloablative HSCT, as measured by incidence of Lactobacillus…
- Trial name
- NCT01010867
- Testing
- Lactobacillus plantarum strains 299 and 299v
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Columbia University
Acute Leukemia in Remission, Myelodysplastic Syndromes
Sirolimus/Tacrolimus Combination After HLA Matched Related Peripheral Blood Stem Cell Transplants
Study Design: To evaluate the efficacy of the combination of sirolimus and tacrolimus as a graft-versus-host disease prophylaxis, the investigators are going to perform a phase II, multicenter clinical trial after human leukocyte…
- Conditions
- Acute Leukemia in Remission, Myelodysplastic Syndromes, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Accelerated-Phase
- Trial name
- NCT01488253
- Testing
- Sirolimus, Tacrolimus
- Where
- South Korea
- Volunteers
- 3 people
- Sponsor
- The Korean Society of Blood and Marrow Transplantation
Epstein-Barr Virus Infection, Post-Transplant Lymphoproliferative Disorder
Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation
Epstein-Barr virus (EBV) DNAemia is a common and potentially serious complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and may progress to EBV-associated lymphoproliferative disorders.
- Trial name
- NCT07368634
- Testing
- EBV-TCR-T Cell Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Daihong Liu
Hematopoietic Stem Cell Transplantation (HSCT), cGVHD
Belumosudil Versus Ruxolitinib for Steroid-Refractory or Breakthrough Hepatic cGVHD
This prospective, randomized, open-label, multicenter trial aims to compare second-line treatment strategies for hepatic cGVHD after allo-HSCT.
- Conditions
- Hematopoietic Stem Cell Transplantation (HSCT), cGVHD, Hepatic cGVHD, Belumosudil
- Trial name
- NCT07794514
- Testing
- Ruxolitinib treatment, Belumosudil treatment, Belumosudil Switch to Ruxolitinib
- Where
- China
- Volunteers
- 170 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Survivorship, Stem Cell Transplant Complications
AlloLife - Life After Transplantation
Survivors of allo HCT can experience long-term survival, which is however limited by a number of late effects. These will be addressed in AlloLife to improve quality of life (QoL) and survival.
- Trial name
- AlloLife (NCT05087784)
- Testing
- Technology supported, coordinated survivorship care using wearable devices, supportive patient-apps and cardio-oncology physician apps
- Volunteers
- 192 people
- Sponsor
- University Hospital, Essen
Bronchiolitis Obliterans Syndrome, Hematologic Malignancy
Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome
Lung is one of the target organs in chronic graft versus host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Trial name
- NCT05413356
- Testing
- Ruxolitinib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
COVID-19, Hematopoietic Stem Cell Transplantation
A Study to Evaluate the Safety and Efficacy of COVID-19 Convalescent Plasma (CCP) Transfusion to Prevent COVID-19 in Adult Recipients Following Hematopoietic Stem Cell Transplantation
The study is to evaluate the safety and efficacy of COVID-19 convalescent plasma (CCP) transfusion to prevent COVID-19 in adult recipients following hematopoietic stem cell transplantation.
- Trial name
- NCT05904067
- Testing
- COVID Convalescent Plasma
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA)
Single Patient Expanded Access Treatment Plan For The Investigational Product Narsoplimab
The purpose of the EAP is to provide access to hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) patients who may benefit from treatment with narsoplimab based on the medical judgement of their…
- Trial name
- NCT04247906
- Testing
- Narsoplimab
- Sponsor
- Omeros Corporation
Lymphoma, Myeloma
Generic Plerixafor Efficacy of Autologous Hematopoietic Stem Cell Transplantation
Generic plerixafor use at reduced-dose for mobilization on HSCT transplant
- Trial name
- NCT06892119
- Testing
- Celrixafor
- Where
- Mexico
- Volunteers
- 6 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Vomiting
A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation
The purpose of this study is to evaluate the efficacy and safety of additional aprepitant to standard antiemetic regimen in Autologous Hematopoietic Stem Cell Transplantation.
- Trial name
- NCT02576327
- Testing
- Tropisetron, Dexamethasone, Aprepitant
- Volunteers
- 130 people
- Sponsor
- Jun Zhu
Blood And Marrow Transplantation
Plerixafor for Stem Cell Mobilization in Normal Donors
The goal of this clinical research study is to learn if treating stem cell donors with filgrastim (G-CSF) and plerixafor (Mozobil®) can cause them to produce a higher number of blood stem cells than filgrastim by itself.
- Trial name
- NCT01818284
- Testing
- Filgrastim, Plerixafor, Apheresis Procedure
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia (AML)
Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation
During the pre-transplantation phase (following completion of consolidation chemotherapy), patients will begin to receive G-CSF at 10 mcg/kg twice daily; leukapheresis will also be given until a target goal for recipient body…
- Trial name
- NCT00363467
- Testing
- G-CSF, Leukapheresis, Busulfan
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Hematopoietic Stem Cell Transplant, Hematologic Diseases
Impact of Prehabilitation in Oncology Via Exercise- Bone Marrow Transplant
The purpose of this study is to determine whether patients are able to participate in a prehabilitation program (prior to the beginning of treatment) which includes: (1) a home-based exercise program or (2) just a prehabilitation…
- Conditions
- Hematopoietic Stem Cell Transplant, Hematologic Diseases, Physical Activity, Prehabilitation
- Trial name
- IMPROVE-BMT (NCT03886909)
- Testing
- Exercise, Prehabilitation Education
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Milton S. Hershey Medical Center
TP53-mutated MDS and AML, Allogeneic Hematopoietic Stem Cell Transplantation
Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation
This study aims to explore the safety and efficacy of selinexor combined with azacitidine for maintenance therapy in TP53 mutant AML/MDS patients following transplantation.
- Trial name
- NCT07094464
- Testing
- Maintenance Therapy with Selinexor and Azacitidine
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Daihong Liu
Hematologic Malignancy, Leukemia, Acute
Screening for Colonization With Resistant Enterobacterales in Neutropenic Patients With Hematologic Malignancies
This is a prospective, observational cohort study to assess the frequency with which neutropenic patients with hematologic malignancies and hematopoietic cell transplant (HCT) recipients are colonized with…
- Conditions
- Hematologic Malignancy, Leukemia, Acute, Neutropenia, Bloodstream Infection
- Trial name
- SCENE (NCT04710212)
- Testing
- No intervention.
- Where
- 6 sites in United States
- Volunteers
- 168 people
- Sponsor
- Duke University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.